JP2004527235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004527235A5 JP2004527235A5 JP2002562384A JP2002562384A JP2004527235A5 JP 2004527235 A5 JP2004527235 A5 JP 2004527235A5 JP 2002562384 A JP2002562384 A JP 2002562384A JP 2002562384 A JP2002562384 A JP 2002562384A JP 2004527235 A5 JP2004527235 A5 JP 2004527235A5
- Authority
- JP
- Japan
- Prior art keywords
- gram
- regulating
- expression
- group
- genetically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 238000000034 method Methods 0.000 claims 10
- 239000012528 membrane Substances 0.000 claims 9
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims 7
- 108010013639 Peptidoglycan Proteins 0.000 claims 7
- 230000027455 binding Effects 0.000 claims 7
- 230000002222 downregulating effect Effects 0.000 claims 6
- 238000002360 preparation method Methods 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 241000606768 Haemophilus influenzae Species 0.000 claims 3
- 241000588655 Moraxella catarrhalis Species 0.000 claims 3
- 241000588650 Neisseria meningitidis Species 0.000 claims 3
- 229940047650 haemophilus influenzae Drugs 0.000 claims 3
- 101150026694 tolQ gene Proteins 0.000 claims 3
- 101150088820 tolR gene Proteins 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 241000350158 Prioria balsamifera Species 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 101150061964 tolA gene Proteins 0.000 claims 2
- 101150014665 tolB gene Proteins 0.000 claims 2
- 241000588832 Bordetella pertussis Species 0.000 claims 1
- 101100242562 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) pal gene Proteins 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101001129465 Homo sapiens Pyroglutamyl-peptidase 1 Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims 1
- 241000588649 Neisseria lactamica Species 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 101100226309 Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) exbB1 gene Proteins 0.000 claims 1
- 101100119307 Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) exbD1 gene Proteins 0.000 claims 1
- 230000006472 autoimmune response Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 101150080665 exbB gene Proteins 0.000 claims 1
- 101150074952 exbD gene Proteins 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 101150115693 ompA gene Proteins 0.000 claims 1
- 101150077062 pal gene Proteins 0.000 claims 1
- 101150024840 rmpM gene Proteins 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0103171.5A GB0103171D0 (en) | 2001-02-08 | 2001-02-08 | Vaccine composition |
| PCT/EP2002/001361 WO2002062378A2 (en) | 2001-02-08 | 2002-02-08 | Hyperblebbing bacterial strains and use thereof for production of vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004527235A JP2004527235A (ja) | 2004-09-09 |
| JP2004527235A5 true JP2004527235A5 (enExample) | 2005-12-22 |
| JP4374190B2 JP4374190B2 (ja) | 2009-12-02 |
Family
ID=9908384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002562384A Expired - Fee Related JP4374190B2 (ja) | 2001-02-08 | 2002-02-08 | ハイパーブレビングな細菌株及びそのワクチン製造のための使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20040116665A1 (enExample) |
| EP (2) | EP1357938B8 (enExample) |
| JP (1) | JP4374190B2 (enExample) |
| AU (1) | AU2002233321A1 (enExample) |
| CA (1) | CA2447905A1 (enExample) |
| DE (1) | DE60233029D1 (enExample) |
| ES (1) | ES2327496T3 (enExample) |
| GB (1) | GB0103171D0 (enExample) |
| WO (1) | WO2002062378A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1179072A2 (en) | 1999-05-19 | 2002-02-13 | Chiron S.P.A. | Combination neisserial compositions |
| MXPA03000822A (es) | 2000-07-27 | 2004-11-01 | Childrens Hosp & Res Ct Oak | Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis. |
| CN1514879A (zh) | 2001-05-15 | 2004-07-21 | ϣ�����ﻯѧ����˾ | 粘膜炎莫拉氏菌(布兰汉氏菌)抗原 |
| EP1444349B1 (en) | 2001-11-16 | 2008-11-12 | ID Biomedical Corporation | Polypeptides of moraxella (branhamella) catarrhalis |
| GB0220194D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| DK1587537T3 (da) | 2003-01-30 | 2012-07-16 | Novartis Ag | Injicerbare vacciner mod multiple meningococ-serogrupper |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| CN101107007B (zh) | 2005-01-27 | 2011-08-17 | 奥克兰儿童医院及研究中心 | 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗 |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| US20080085055A1 (en) * | 2006-10-06 | 2008-04-10 | Cerosaletti Cathleen D | Differential cluster ranking for image record access |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| WO2009049013A2 (en) * | 2007-10-09 | 2009-04-16 | Tufts University | Cholera vaccines |
| HRP20120433T1 (en) | 2007-10-19 | 2012-07-31 | Novartis@Ag | Meningococcal vaccine formulations |
| AU2009215364B2 (en) | 2008-02-21 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Meningococcal fHBP polypeptides |
| SI2268618T1 (sl) | 2008-03-03 | 2015-09-30 | Novartis Ag | Spojine in sestavki kot modulatorji aktivnosti TLR |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| AU2009329193A1 (en) | 2008-12-17 | 2011-07-14 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
| US8047509B2 (en) | 2009-04-08 | 2011-11-01 | Uop Llc | Vapor-liquid contacting apparatuses with vortex contacting stages |
| CA2765112A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
| WO2011024072A2 (en) | 2009-08-27 | 2011-03-03 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
| AU2010288239B2 (en) | 2009-08-27 | 2014-01-16 | Novartis Ag | Adjuvant comprising aluminium, oligonucleotide and polycation |
| US9950062B2 (en) | 2009-09-02 | 2018-04-24 | Glaxosmithkline Biologicals Sa | Compounds and compositions as TLR activity modulators |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| GB0917002D0 (en) * | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
| GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
| CN102724988B (zh) | 2009-09-30 | 2014-09-10 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽的表达 |
| CA2779816A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| JP5814933B2 (ja) | 2009-12-15 | 2015-11-17 | ノバルティス アーゲー | 免疫増強化合物の均質な懸濁物およびその使用 |
| WO2012020326A1 (en) | 2010-03-18 | 2012-02-16 | Novartis Ag | Adjuvanted vaccines for serogroup b meningococcus |
| EA031379B1 (ru) | 2010-03-23 | 2018-12-28 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| CA2810971C (en) | 2010-09-10 | 2020-11-03 | Novartis Ag | Developments in meningococcal outer membrane vesicles |
| GB201017519D0 (en) * | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
| EP2505208A1 (en) | 2011-04-01 | 2012-10-03 | University of Graz | Vaccine against Pasteurellaceae |
| US20150147356A1 (en) | 2011-05-12 | 2015-05-28 | Alan Kimura | Antipyretics to enhance tolerability of vesicle-based vaccines |
| MX2014008988A (es) | 2012-02-02 | 2014-08-27 | Novartis Ag | Promotores para aumento de expresion de proteinas en meningococo. |
| US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
| SG10201608980YA (en) | 2012-04-26 | 2016-12-29 | Novartis Ag | Antigens and antigen combinations |
| BR112015005056A2 (pt) | 2012-09-06 | 2017-11-21 | Novartis Ag | vacinas de combinação com sorogrupo b meningococcus e d/t/p |
| AU2013320313B2 (en) | 2012-09-18 | 2018-07-12 | Glaxosmithkline Biologicals Sa | Outer membrane vesicles |
| US10877033B2 (en) | 2013-06-18 | 2020-12-29 | Oxford University Innovation Limited | Method of detecting the presence or absence of autoantibodies |
| GB201313249D0 (en) * | 2013-07-25 | 2013-09-11 | Isis Innovation | Method |
| CN106661092B (zh) | 2014-02-28 | 2021-07-06 | 葛兰素史密丝克莱恩生物有限公司 | 修饰的脑膜炎球菌fHbp多肽 |
| WO2016176573A1 (en) * | 2015-04-30 | 2016-11-03 | Board Of Regents, The University Of Texas System | Antibacterial polypeptide libraries and methods for screening the same |
| EP3263695A1 (en) * | 2016-06-29 | 2018-01-03 | GlaxoSmithKline Biologicals SA | Immunogenic compositions |
| US12036285B2 (en) | 2016-11-25 | 2024-07-16 | Glaxosmithkline Biologicals Sa | Immunogenic conjugates and use thereof |
| JP6963335B2 (ja) * | 2018-02-20 | 2021-11-05 | 株式会社山田養蜂場本社 | 膜小胞組成物の製造方法 |
| EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| CN120118819B (zh) * | 2025-05-15 | 2025-08-12 | 上海羽冠生物技术有限公司 | 一种经修饰的百日咳鲍特菌菌株及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
| US4271147A (en) | 1980-01-10 | 1981-06-02 | Behringwerke Aktiengesellschaft | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same |
| US5173294A (en) | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
| JPH01125328A (ja) | 1987-07-30 | 1989-05-17 | Centro Natl De Biopreparados | 髄膜炎菌ワクチン |
| DK0539492T3 (da) | 1990-07-16 | 2003-09-22 | Univ North Carolina | Antigene jernundertrykkelige proteiner fra N. meningitidis beslægtet med hemolysinfamilien af toksiner |
| US5912336A (en) | 1990-08-23 | 1999-06-15 | University Of North Carolina At Chapel Hill | Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis |
| US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
| DE69313134T2 (de) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| GB9224584D0 (en) | 1992-11-23 | 1993-01-13 | Connaught Lab | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases |
| JP3429313B2 (ja) | 1993-05-18 | 2003-07-22 | オハイオ・ステイト・リサーチ・ファウンデーション | 中耳炎ワクチン |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| US6265567B1 (en) | 1995-04-07 | 2001-07-24 | University Of North Carolina At Chapel Hill | Isolated FrpB nucleic acid molecule |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
| US6180111B1 (en) * | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
| GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
| BR9609882A (pt) * | 1995-08-04 | 1999-07-27 | Univ Guelph | Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana |
| US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
| US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
| US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
| FR2751000B1 (fr) | 1996-07-12 | 1998-10-30 | Inst Nat Sante Rech Med | Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques |
| US6558677B2 (en) * | 1996-10-15 | 2003-05-06 | Wendell D. Zollinger | Vaccine against gram negative bacteria |
| EP0983207A1 (de) | 1997-05-23 | 2000-03-08 | L & P Swiss Holding Company | Verfahren und vorrichtung zur herstellung von taschenfederkernen |
| BR9809914A (pt) | 1997-06-03 | 2001-09-18 | Connaught Lab | Genes de moracella receptores de lactoferrina |
| GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
| GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| MX343752B (es) | 1998-05-01 | 2016-11-22 | Novartis Vaccines & Diagnostics Inc | Antigenos de neisseria meningitidis y composiciones que los contienen. |
| GB9809683D0 (en) | 1998-05-06 | 1998-07-01 | Smithkline Beecham Biolog | Novel compounds |
| CA2328429A1 (en) | 1998-05-13 | 1999-11-18 | Smithkline Beecham Biologicals S.A. | Basb028 polypeptides and polynucleotides encoding therefor from moraxella catarrhalis |
| GB9810285D0 (en) | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
| GB9811260D0 (en) | 1998-05-26 | 1998-07-22 | Smithkline Beecham Biolog | Novel compounds |
| EP1082435B1 (en) | 1998-06-03 | 2006-10-04 | GlaxoSmithKline Biologicals S.A. | Proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses |
| GB9812163D0 (en) | 1998-06-05 | 1998-08-05 | Smithkline Beecham Biolog | Novel compounds |
| GB9812440D0 (en) | 1998-06-09 | 1998-08-05 | Smithkline Beecham Biolog | Novel compounds |
| GB9818004D0 (en) | 1998-08-18 | 1998-10-14 | Smithkline Beecham Biolog | Novel compounds |
| US6693186B2 (en) * | 1998-09-01 | 2004-02-17 | Antex Biologics Inc | Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof |
| GB9820003D0 (en) | 1998-09-14 | 1998-11-04 | Smithkline Beecham Biolog | Novel compounds |
| GB9820002D0 (en) | 1998-09-14 | 1998-11-04 | Smithkline Beecham Biolog | Novel compounds |
| CA2347849C (en) | 1998-10-22 | 2013-06-25 | The University Of Montana | Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof |
| WO2000042191A2 (en) | 1999-01-15 | 2000-07-20 | Smithkline Beecham Biologicals S.A. | Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| US6518037B2 (en) * | 1999-11-12 | 2003-02-11 | University Of Iowa Research Foundation | Two-component system that controls bacterial membrane synthesis |
-
2001
- 2001-02-08 GB GBGB0103171.5A patent/GB0103171D0/en not_active Ceased
-
2002
- 2002-02-08 US US10/467,421 patent/US20040116665A1/en not_active Abandoned
- 2002-02-08 ES ES02700219T patent/ES2327496T3/es not_active Expired - Lifetime
- 2002-02-08 AU AU2002233321A patent/AU2002233321A1/en not_active Abandoned
- 2002-02-08 DE DE60233029T patent/DE60233029D1/de not_active Expired - Lifetime
- 2002-02-08 EP EP02700219A patent/EP1357938B8/en not_active Expired - Lifetime
- 2002-02-08 WO PCT/EP2002/001361 patent/WO2002062378A2/en not_active Ceased
- 2002-02-08 CA CA002447905A patent/CA2447905A1/en not_active Abandoned
- 2002-02-08 EP EP09165364A patent/EP2141227A3/en not_active Withdrawn
- 2002-02-08 JP JP2002562384A patent/JP4374190B2/ja not_active Expired - Fee Related
-
2006
- 2006-05-15 US US11/434,027 patent/US20060204520A1/en not_active Abandoned
-
2008
- 2008-10-22 US US12/256,021 patent/US20090155887A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rietschel et al. | Endotoxin: historical perspectives | |
| Evans et al. | Plasmid-controlled colonization factor associated with virulence in Esherichia coli enterotoxigenic for humans | |
| Colwell et al. | Viable but non-culturable Vibrio cholerae O1 revert to a cultivable state in the human intestine | |
| Bakaletz et al. | Frequency of fimbriation of nontypable Haemophilus influenzae and its ability to adhere to chinchilla and human respiratory epithelium | |
| Daegelen et al. | Tracing ancestors and relatives of Escherichia coli B, and the derivation of B strains REL606 and BL21 (DE3) | |
| US5631010A (en) | Genetically stable cholera vaccines with deletions of ctxA, recA and attRS1 | |
| US20030216338A1 (en) | Bacteriophage having multiple host range | |
| JP2011514155A5 (enExample) | ||
| JPH02504461A (ja) | 組換えミコバクテリア・ワクチン | |
| WO1999047167A1 (en) | Double mutant enterotoxin for use as an adjuvant | |
| JPS5877821A (ja) | コレラワクチンおよびその製造方法 | |
| JPS58501325A (ja) | 腸疾患用免疫賦与性経口ワクチン | |
| Pumpens | Single-stranded RNA phages: From molecular biology to nanotechnology | |
| HU225644B1 (en) | Attenuated bacteria and vaccines containing thereof | |
| US5698416A (en) | Methods for production of antigens under control of temperature-regulated promotors in enteric bacteria | |
| IE913912A1 (en) | Avirulent microbes and uses therefor: salmonella typhi | |
| EP0573527A1 (en) | Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e. coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e. coli bacteria in humans | |
| JP3675824B2 (ja) | 温度調節的手法で発現されるタンパク質を生産するバクテリアの培養方法 | |
| Kirov et al. | Electron microscopic examination of factors influencing the expression of filamentous surface structures on clinical and environmental isolates of Aeromonas veronii biotype sobria | |
| Bottone et al. | Yersinia | |
| CN111925424A (zh) | 日本乙型脑炎病毒基因工程亚单位疫苗、其制备方法及应用 | |
| CN118697861A (zh) | 一种嵌合表达OmpUT-LptDEP联合抗原的弧菌基因工程活菌疫苗及其制备方法和应用 | |
| Kaura et al. | Enterotoxigenicity and invasiveness of Salmonella species | |
| Dennison et al. | Host specificities of RNA phages | |
| CN112029695B (zh) | 一种大菱鲆来源的副乳房链球菌及其应用 |